^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

    Excerpt:
    ...- Patient must have confirmed HER2 overexpression or gene-amplified tumor via immunohistochemistry [IHC] with IHC 3+ or IHC 2+ with confirmatory fluorescence in situ hybridization [FISH]+ or [ISH]+...
    Trial ID:
    NCT03429101
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib

    Published date:
    08/28/2020
    Excerpt:
    In terms of drug efficacy, high mRNA expression of HER2 was the most powerful predictor of poziotinib response (median progression-free survival [PFS): 4.63 months [high] vs. 2.56 [low]; p < .001). In a combination prediction model, median PFS of intrinsic subtypes except Her2-E with high HER2 mRNA expression without PIK3CA genetic alteration was 6.83 months and that of the remaining group was 1.74 months (p < .001).
    DOI:
    10.1007/s10549-020-05891-0
    Trial ID:
    NCT02418689